Clinical Trial Detail

NCT ID NCT02383212
Title Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Carboplatin + Cemiplimab + Docetaxel

Carboplatin + Cemiplimab + Pemetrexed Disodium

Cemiplimab + Cyclophosphamide + Sargramostim

Cemiplimab + Cyclophosphamide

Cemiplimab

Carboplatin + Cemiplimab + Paclitaxel

Cemiplimab + Docetaxel

Age Groups: senior adult

No variant requirements are available.